Australian TGA Approval Decision Expected in Early 2020

ENGLEWOOD, CO / ACCESSWIRE / April 24, 2019 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the submission of ZolpiMist™ (zolpidem tartrate oral spray) for regulatory approval to the Australian Therapeutic Goods Administration (TGA). SUDA Pharmaceuticals Ltd (”SUDA”), which holds the global ZolpiMist sublicense outside the U.S. and Canada, has made this submission and further disclosed that the TGA has accepted the ZolpiMist Marketing Authorisation Application (MAA) for review and the review is underway.

Aytu BioScience previously announced its partnership with SUDA Pharmaceuticals as the licensee of ZolpiMist outside the U.S. and Canada, and SUDA already has multiple sublicensing agreements in place around the world. This submission to the Australian TGA represents SUDA’s first direct regulatory submission, and the expected review period is 255 days. Accordingly, a decision by TGA is expected in early calendar 2020.

Josh Disbrow, Chief Executive Officer of Aytu BioScience commented, ”We congratulate SUDA Pharmaceuticals on their successful submission of the ZolpiMist regulatory file to the Australian TGA. As the TGA is one of the world’s most rigorous regulatory bodies, we are encouraged by the agency’s prompt preliminary assessment and acknowledgement of the file’s completeness and readiness for full review. We look forward to the potential approval of ZolpiMist early next year following the completion of TGA’s review.”

Aytu recently announced the global licensing agreement for ZolpiMist with SUDA. The Aytu-SUDA licensing agreement calls for SUDA to lead commercial development and sublicensing efforts for ZolpiMist in major territories outside the United States and Canada, including Europe, Asia, Australia, and Latin America. As specified in the companies’ global licensing agreement, SUDA will pay Aytu a portion of each upfront and milestone payment received from sublicensees, and Aytu will receive ongoing royalty payments on sales generated by SUDA and SUDA’s sublicensees as ZolpiMist is launched in their territories.

SUDA has already signed sublicensing agreements in key markets with large, multi-national pharmaceutical companies and has agreements in place in Brazil, China, Chile, and throughout Southeast Asia.

SUDA is in negotiations with pharmaceutical companies to sublicense ZolpiMist in additional countries in South America, as well as in Europe (specifically in Spain, Italy, France, and Germany), Korea, the Middle East, North Africa, UAE, and Kuwait.

The global sleep aid market is currently estimated at almost $50 billion in annual revenue, and annual revenue is estimated to reach nearly $80 billion in 2022.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs. The company currently markets Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”). Aytu also has exclusive U.S. and Canadian rights to ZolpiMist™, an FDA-approved, commercial-stage prescription sleep aid indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Aytu recently acquired exclusive U.S. commercial rights to Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. Tuzistra XR is a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an extended-release oral suspension. Additionally, Aytu is developing MiOXSYS®, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside of the U.S. where it is a CE Marked, Health Canada cleared, Australian TGA approved, Mexican COFEPRAS approved product, and Aytu is planning U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu’s strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.

About SUDA Pharmaceuticals

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA’s product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the U.S. and Canada. Other products SUDA has in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ”may,” ”will,” ”should,” ”forecast,” ”could,” ”expect,” ”suggest,” ”believe,” ”estimate,” ”continue,” ”anticipate,” ”intend,” ”plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks relating to gaining market acceptance of our products, obtaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ”Risk Factors” in Part I, Item 1A of the company’s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Investors:

James Carbonara
Hayden IR
(646)-755-7412
james@haydenir.com

SOURCE: Aytu BioScience, Inc.

ReleaseID: 542793

VANCOUVER, BC / ACCESSWIRE / April 24, 2019 / 92 Resources Corp. (the “Company”) (TSX-V: NTY) (OTCQB: RGDCF) (FSE: R9G2) announces an amendment the terms of the September 2018 Option Agreement (the “Agreement”) with Osisko Mining Inc. (“Osisko”) for the eastern FCI Property (“FCI East”) to include an additional 83 claims (4,253 hectares) herein referred to as “FCI West”. The Company now holds three contiguous claim blocks: FCI West, FCI East, and Corvette, collectively referred to as the “Corvette-FCI Property” and extending for more than 25 km along the Lac Guyer Greenstone Belt within the James Bay Region of Quebec. Situated approximately 10 km south of the all-season Trans-Taiga Road and powerline, the FCI West block is adjacent to the south of Midland Exploration’s Mythril Property (TSX-V: MD) and immediately east of Azimut Exploration’s Pikwa Property (TSX-V: AZM). See map at the link below:

https://92resources.com/wp-content/uploads/2019/04/fcinr.jpg

The Amended Agreement retains the same Option terms as originally disclosed for FCI East (see news release dated September 4th, 2018); however, now includes an additional 83 claims which comprise the FCI West claim block. Therefore, the Company now holds the Option to acquire up to a 75% interest over Osisko’s entire FCI Property (FCI West – 83 claims, and FCI East – 28 claims).

The Company believes the Corvette-FCI Property to have considerable potential for gold-polymetallic mineralization similar to that recently discovered on the adjacent Mythril Property held by Midland Exploration Inc.

Exploration highlights at FCI West include:

Parallel east-west elongate trends of gold and copper mineralization over 10 km in length

The Golden Gap Prospect (northern trend) with historical results including,

from 3.1 to 108.9 g/t Au in outcrop

10.5 g/t Au over 7 m in drill hole FCI-07-03

14.5 g/t Au over 2 m in channel sample

The Tyrone-T9 (Copper) Prospect (southern trend) includes 1.15% Cu over 2.1 m in channel sample

The FCI West block hosts a documented sixteen (16) base and precious metal showings (SIGEOM), which highlight parallel gold and copper dominated exploration trends of greater than 10 km in length. The Golden Gap Prospect is the most advanced target on the Property and includes a drill intercept of 10.5 g/t Au over 7 m (FCI-07-003) as well as 14.5 g/t over 2 m in channel sampling. FCI West is also host to numerous high-grade surface occurrences including a grab sample of 108.9 g/t Au in outcrop. Despite the significant number of showings at FCI West, the Company considers the exploration to date to be at an early stage.

The exploration potential of FCI West is further confirmed by its proximity to the Mythril Property, where significant Cu-Au-Mo-Ag mineralization was discovered in the fall of 2018 by Midland Exploration Ltd.; 16.7% Cu, 16.8 g/t Au, and 3.04% Mo (select, separate samples – outcrop and boulder). The newly acquired FCI West block covers approximately 11 km along the southern portions of the same geological units that host the Mythril discovery. Similarly, the FCI East and Corvette claim blocks also cover a portion of the unit’s eastern contact. These areas have seen only limited exploration attention.

Management cautions that past results or discoveries on adjacent properties (i.e. Mythril) may not necessarily be indicative to the presence of mineralization on the Company’s properties (i.e. FCI or Corvette).

Company President & CEO Adrian Lamoureux comments: “We are thrilled to have expanded our land position in the region, increasing our footprint. With the recent high-grade Cu-Au-Mo discoveries in the area by Midland Exploration and the established Au-Cu potential at FCI West, we see significant opportunity to advance several exceptional gold and polymetallic prospects over a strike length of more than a 10 km within the Lac Guyer Greenstone Belt.”

The Company intends to complete initial exploration this summer at FCI West and is in the process of receiving the historical dataset from Osisko. Exploration is anticipated to be completed as part of the programs planned at FCI East and Corvette during the summer months. Although there is demonstrated gold and copper potential at FCI West, the lithium potential has never been assessed. As FCI West hosts the same underlying geology as that of FCI East as well as Corvette, where high-grade spodumene mineralization has been identified, the lithium potential is also considered favorable. During 2019, the Lac Guyer Greenstone Belt and surrounding properties are anticipated see significant exploration activity from multiple companies as the magnitude of the Mythril style copper-gold mineralization unfolds.

Collectively, the Company’s land position in the area now comprises one contiguous claim block consisting of 283 claims totalling 14,496 hectares, and includes the wholly owned Corvette Property, as well as the FCI East and FCI West property Options. The Company’s land package (collectively the “Corvette-FCI Property”) is one of the largest and most strategic positions in this developing base and precious metal district.

Terms of Agreement

Under the terms of the Amended Agreement, the Company may earn a 75% interest in an additional eighty-three (83) claims that comprise Osisko’s FCI West Property by satisfying the original terms and conditions as previously announced for the FCI East Property (see news disclosure dated September 4th, 2018). Therefore, the FCI West Property has now been incorporated under the original terms and conditions of the Agreement disclosed September 4th, 2018 and no additional share, cash, or work commitment is required by the Company. The Amended Agreement remains subject to TSX Venture Exchange approval.

About 92 Resources Corp.

92 Resources Corp is a modern energy solution company, focused on acquiring and advancing strategic and prospective modern energy related projects. The Company currently holds four principal assets in Canada: the Corvette (plus FCI Option) and Pontax lithium-gold properties in Quebec, the Golden Frac Sand Property, BC, and the Hidden Lake Lithium Property, NWT, currently under option to Far Resources Ltd. The Company also recently acquired the Silver Sands Vanadium Property in British Columbia.

NI 43-101 Disclosure

Darren L. Smith, M.Sc., P. Geo., of Dahrouge Geological Consulting Ltd. and member of the Board of Advisors to the Company, a Qualified Person as defined by National Instrument 43-101, supervised the preparation of the technical information in this news release.

For further information, please contact Adrian Lamoureux, President & CEO at Tel: 778-945-2950, E-mail: adrian@92resources.com or visit www.92resources.com.

On Behalf of the Board of Directors,
“ADRIAN LAMOUREUX”
Adrian Lamoureux, President & CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements:

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements”. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

SOURCE: 92 Resources Corp.

ReleaseID: 542764

~Established Customer Base and Revenue Growth a Great Match for TIMIA’s Non-Dilutive Capital Solution~

VANCOUVER, BC / ACCESSWIRE / April 24, 2019 / TIMIA Capital Corporation (“TIMIA” or the “Company”) (TSX-V:TCA / OTC:TIMCF) today announced that it has entered into a three year, $2 million investment facility for Victoria, BC-based software company, Echosec Systems Inc., (“Echosec”). The initial disbursement amount of $1 million has been advanced and a further $1,000,000 is to be disbursed upon certain milestones being met over the term of the agreement.

“Our flexible capital structure allows Echosec to increase their marketing and sales efforts to expand within their existing market, and explore new promising opportunities,” said Greg Smith, CIO of TIMIA. “We’re providing growth capital to a great company who understand how to provide value and service through their software with established customers ranging from small business to enterprise.”

“The cost of capital includes critical factors such as dilution, debt servicing and access to more capital as we scale,” said Karl Swannie, CEO of Echosec. “Finding flexible and non-dilutive financing solutions was our goal, and TIMIA provided the capital within a framework that worked for us and our team. We look forward to working with TIMIA going forward as a financial partner.”

TIMIA is continuously seeking new and exciting investments in the software as a service or SaaS industry. Under TIMIA’s revenue-based financing model, TIMIA advances capital to a SaaS business with a recurring revenue stream that allows the portfolio company to make monthly payments to TIMIA that are a combination of principal and interest with a repayment schedule sculpted to the portfolio company’s revenue streams. The amounts advanced are secured and may be repaid early. The Company expects to make further investments in the coming months, in the pursuit of its business model, which is to earn a combination of monthly payments and periodic gains on investments.

About Echosec Systems Inc.

Echosec is a web-based data discovery platform that helps organizations detect online data for threat intelligence. Aggregating and mapping content from hundreds of sources including social media, blogs, news, and the Dark Web (with Beacon), Echosec gives users instant visibility into any place on earth through a digital window. Echosec uses machine learning technology to recognize Images and keywords so users get notified when specific content is posted. Beacon is the newest service offering from Echosec, and is a dark web search platform. For more information, please visit: https://www.echosec.net.

About TIMIA Capital Corporation

TIMIA Capital Corporation is a specialty finance company that provides growth capital to technology companies in exchange for payments based on monthly revenue. This alternative financing option complements both debt and equity financing, while allowing entrepreneurs and existing stakeholders to retain ownership and control of their business. TIMIA’s singular focus is the fast growing, global, business-to-business Software-as-a-Service (or SaaS) segment. We align ourselves with entrepreneurial management teams growing their sales from $1 Million to $10 Million in Annual Recurring Revenue. For more information about TIMIA Capital Corporation, please visit www.timiacapital.com

For more information, please contact:

Darren Seed
Vice President, Capital Markets & Communications
Mike Walkinshaw, CEO
TIMIA Capital Corporation
604.398.8839
IR@timiacapital.com

Paula Hingley
Director of Marketing & Communications
Echosec
250.213.9916
paula@echosec.net

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Information

Certain information and statements in this news release contain and constitute forward-looking information or forward-looking statements as defined under applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements normally contain words like ‘believe’, ‘expect’, ‘anticipate’, ‘plan’, ‘intend’, ‘continue’, ‘estimate’, ‘may’, ‘will’, ‘should’, ‘ongoing’ and similar expressions, and within this news release include any statements (express or implied) respecting further disbursements upon certain milestones being met over the term of the agreement and expectations regarding making further investments in the coming months. Forward-looking statements are not guarantees of future performance, actions, or developments and are based on expectations, assumptions and other factors that management currently believes are relevant, reasonable and appropriate in the circumstances, including, without limitation, the following assumptions: that the Company and its investee companies are able to meet their respective future objectives and priorities, assumptions concerning general economic growth and the absence of unforeseen changes in the legislative and regulatory framework for the Company. Although management believes that the forward-looking statements are reasonable, actual results could be substantially different due to the risks and uncertainties associated with and inherent to Timia’s business. Material risks and uncertainties applicable to the forward-looking statements set out herein include, but are not limited to, the Company having insufficient financial resources to achieve its objectives; availability of further investments that are appropriate for the Company on terms that it finds acceptable or at all; successful completion of exits from investments on terms that constitute a gain when no such exits are currently anticipated; intense competition in all aspects of business; reliance on limited management resources; general economic risks; new laws and regulations and risk of litigation. Although Timia has attempted to identify factors that may cause actual actions, events or results to differ materially from those disclosed in the forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, predicted, estimated or intended. Also, many of the factors are beyond the control of Timia. Accordingly, readers should not place undue reliance on forward-looking statements. Timia undertakes no obligation to reissue or update any forward-looking statements as a result of new information or events after the date hereof except as may be required by law. All forward-looking statements contained in this news release are qualified by this cautionary statement.

SOURCE: TIMIA Capital Corporation

ReleaseID: 542813

VANCOUVER, BC / ACCESSWIRE / April 24, 2019 / Universal Copper Ltd. (‘Universal Copper’ or the ‘Company’) (TSX Venture: UNV) (Frankfurt: 3TA1), further to its press release of February 20, 2019, is pleased to announce that it has entered into an asset purchase agreement (the ‘Asset Purchase Agreement’), dated April 22, 2019, with MAX Resources Corp. (TSX Venture: MXR) (‘MAX’) and Gachala Columbia Corp., a wholly owned subsidiary of MAX pursuant to which the Company will acquire (the ‘Transaction’) a 100% interest in the 7 mineral license applications comprising the North Block of MAX’s Gachala Copper Project, 60 km east of Bogota, Colombia (the ‘Claims’).

Under the terms of the Asset Purchase Agreement, the Company will issue to MAX in exchange for the Claims, 6,000,000 common shares of the Company, having an approximate value of $600,000 based on the current trading price of the Company’s common shares on the TSX Venture Exchange. The closing of the Asset Purchase Agreement is subject to customary closing conditions including the receipt of third party and regulatory approval, the receipt of a satisfactory title opinion and the approval of the TSX Venture Exchange. Once issued, the 6,000,000 common shares will be subject to a hold period of four months and a day from the date of issuance.

On the closing of the Asset Purchase Agreement, the Company will have approximately 41,977,275 common shares issued and outstanding. The Company anticipates that, as a result of the Transaction, MAX will own 14.3% of the issued shares and will become an insider of the Company. The Transaction is an arm’s length transaction. No finder’s fees will be paid in connection with the Transaction.

Subject to the completion of the transaction, the Company intends to spend approximately $50,000 on its first phase exploration at Gachala. The Company also intends to spend approximately $275,000 on a drill program at its Poplar project.

For additional information, please visit the Company’s website at www.universalcopper.com

ON BEHALF OF THE BOARD OF DIRECTORS

‘Clive Massey’

Clive H. Massey
President & CEO

For further information, please contact: Investor Relations
Phone: (604) 341-6870

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains ‘forward-looking statements’. Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.

Except for the historical information presented herein, matters discussed in this news release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements that are preceded by, followed by, or that include such words as ‘estimate,’ ‘anticipate,’ ‘believe,’ ‘plan’ or ‘expect’ or similar statements are forward-looking statements. This forward-looking information includes, or may be based upon estimates, forecasts and statements of management’s expectations with respect to, among other things, the completion of the proposed transaction with Max, the issuance of permits, the size and quality of mineral resources, future trends for the company, progress in development of mineral properties, future production and sales volumes, capital costs, mine production costs, demand and market outlook for metals, future metal prices and treatment and refining or milling charges, the outcome of legal proceedings, the timing of exploration, development and mining activities, acquisition of shares in other companies and the financial results of the company. Other risks include risks associated with seeking the capital necessary to complete the proposed transaction, the regulatory approval process, competitive companies, future capital requirements and the Company’s ability and level of support for its exploration and development activities. There can be no assurance that the Company will be able to complete the proposed transaction, that the Company’s exploration efforts will succeed or the Company will ultimately achieve commercial success. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company’s periodic reports filed from time-to-time.

SOURCE: Universal Copper Ltd.

ReleaseID: 542815

LOS ANGELES / ACCESSWIRE / April 24, 2019 / The executive heads at PaymentCloud, a leading payment processing company adept at securing hard-to-place merchant accounts, are building a brand based on the happiness and success of their merchants. Shawn Silver, CEO, and Chelsie Cooper, South-East Regional President, comprise the go-getting team with a scalable infrastructure and decades of combined experience in the space. The need for a merchant account provider of this sort was born from the swell in high-risk business owners finding it increasingly difficult to receive credit card processing for their company, both retail and e-commerce.

Cooper has been immersed in the industry of hard-to-place merchant account providers since birth. Her father created his own ISO and inadvertently introduced her to the world of payments, instilling in her a drive for success. She sat down to discuss her passion for the space. “I have an internal fire to achieve,” explains Cooper. “I had to grind it out and be pretty gritty when it comes to learning the skills and becoming a specialist in this space, and doing the same thing again and again and again to perfect it.”

Matching her determination with his own, Silver initiated the partnership and added his expertise in high-risk payments and mitigation to the mix. About creating PaymentCloud, Silver lamented on his eagerness to jump back into the industry. “I was just ready to go back into business and be creative again. I enjoy building things and I enjoy being able to create something at work.” From the beginning of his journey in merchant services, Shawn has loved the intensity and challenge of handling high-risk accounts. The strict underwriting, risk reduction and innovative integrations require a heightened attention and allowing for creative problem-solving to thrive.

In their relationship moving forward, Silver divulges that “Our goals are aligned and I’m really looking forward to accomplishing a lot of great things.” These two motivated and intelligent individuals complement each other seamlessly. Together, they will continue to accomplish momentous things because of their passion, energy and strategic innovation.

About PaymentCloud

PaymentCloud has the size, scale and technology to differentiate itself from other merchant account providers. With two cross-country locations and almost 40 employees, they facilitate the growth and success of high-risk merchant accounts. On the merchant end, the easy application, transparent steps toward approval and various integration options allow for them to curate the best solutions for their business. While on the partnership side of things, their dedicated division works with over 80 percent of top digital ISOs who utilize their hard-to-place program. A huge part of maintaining success in this arena is due to the seamless submission process through their new online agent dashboard Stratus, which allows efficient boarding and management tools with just the click of a button.

Meet the Executives

This upcoming week, Chelsie Cooper will be accepting her award as one of Electronic Transactions Association’s (ETA) 2019 Forty Under 40 honorees at the premier event for payment industry professionals, TRANSACT. She will be walking the floor at the exhibition hall as well as hosting meetings with current and prospective partners. For an opportunity to meet Chelsie Cooper, Shawn Silver and the team at TRANSACT and to discuss partnership opportunities with PaymentCloud, follow the link below.

Schedule a Meeting

SOURCE: PaymentCloud

ReleaseID: 542820

MIT’s David H. Koch Institute Professor; world-renowned scientist and bio-entrepreneur
Anticipating collaborative projects with Avalon

FREEHOLD, NJ / ACCESSWIRE / April 24, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Robert S. Langer, Sc.D., to its Scientific and Clinical Advisory Board.

Dr. Robert S. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (M.I.T.) (being an Institute Professor is the highest honor that can be awarded to a faculty member). Dr. Langer is a world-renowned scientist and entrepreneur with a wide range of experience and expertise in the healthcare, biotechnology and pharmaceutical industries. The author of more than 1,400 journal articles, Dr. Langer is a pioneer in tissue engineering, regenerative medicine, cellular technologies and therapeutics, with over 1,275 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 350 pharmaceutical, chemical, biotechnology and medical device companies. This achievement, amongst others, has earned him the nickname “the Edison of Medicine” by the Harvard Business Review.

Dr. Langer served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 to 2002 and as its Chairman from 1999 to 2002. He has received numerous major awards, including the 2006 United States National Medal of Science; the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers; and the 2008 Millennium Prize, the world’s prestigious technology prize. He is also the only engineer to receive the Gairdner Foundation International Award; 72 recipients of this award have subsequently received a Nobel Prize. Among numerous other awards Dr. Langer has received are the Dickson Prize for Science (2002); the Heinz Award for Technology, Economy and Employment (2003); the Harvey Prize (2003); the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright); the General Motors Kettering Prize for Cancer Research (2004); the Dan David Prize in Materials Science (2005); the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research; induction into the National Inventors Hall of Fame (2006); the Max Planck Research Award (2008); and the Prince of Asturias Award for Technical and Scientific Research (2008). In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being ”one of history’s most prolific inventors in medicine.” In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and the National Academy of Sciences. He is one of very few people ever elected to all three United States National Academies and the youngest in history (at age 43) to ever receive this distinction.

Forbes magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Discover magazine (2002) named him as one of the 20 most important people in this area. Forbes magazine (2002) selected Dr. Langer as one of the 15 innovators worldwide who will reinvent our future. Time magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best). Parade magazine (2004) selected Dr. Langer as one of six ”Heroes whose research may save your life.” Dr. Langer has received honorary doctorates from Harvard University, Yale University, and other prestigious academic institutions worldwide. He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in chemical engineering.

”We are honored and excited to welcome Dr. Langer to our Scientific and Clinical Advisory Board at this strategically determinative time of Avalon GloboCare’s development,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. ”Dr. Langer is one of the most accomplished scientists in the world. His experience, expertise, and leadership in successfully guiding biomedical programs from research stage through commercialization will bring an invaluable asset to our company and subsidiaries as we pursue leadership in exosome technology, regenerative medicine, and cellular therapy sectors,” added Dr. Jin.

”I am delighted to become scientific and clinical advisor of Avalon GloboCare,” said Dr. Langer. ”I believe that Avalon GloboCare is poised to make substantial contribution and impact in the fields of exosome technology, liquid biopsy, and cellular immunotherapy. I look forward to helping the company continue to advance its mission of accelerating translational research, clinical development, and commercialization of innovative cell-based technologies and therapeutics,” commented Dr. Langer.

About Avalon GloboCare Corp.

Avalon GloboCare Corp. (NASDAQ: AVCO) is a leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (”liquid biopsy”), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.

Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com

Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
avco@crescendo-ir.com

SOURCE: Avalon GloboCare Corp.

ReleaseID: 542692